Eris buys 51 percent stake in Swiss Parenterals for Rs 637.5 crore
New Delhi: Eris Lifesciences has said it has acquired a 51 per cent stake in Swiss Parenterals for Rs 637.5 crore.
Ahmedabad-based Swiss Parenterals is a leading player in the sterile injectables business in over 80 emerging markets across Africa, the Asia Pacific and Latin America.
It has two facilities in Gujarat, which produce a wide range of sterile injectable formulations.
"The acquisition of Swiss Parenterals will help us strengthen our India footprint through the launch of a domestic Injectables-focused Branded Formulations business," Eris Lifesciences Chairman and MD Amit Bakshi said in a statement.
Besides, the emerging markets focus of Swiss Parenterals complements Eris's India focus very well, he added.
Eris Lifesciences has expanded its Sterile Injectables footprint through the acquisition of a 51 per cent equity stake in Swiss Parenterals Ltd for a consideration of Rs 637.50 crore, the company said in a statement.
Eris reported a 1 percent increase in its consolidated profit after tax (PAT) at Rs 101 crore for the third quarter ended December 2023.
It had reported a PAT of Rs 100 crore in the year-ago period.
Its revenue rose to Rs 486 crore from Rs 423 crore in the October-December quarter of 2022-23.
Original news source: https://www.ptinews.com/story/business/eris-acquires-51-pc-stake-in-swiss-parenterals-for-rs-637-5-cr/1287866
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.